Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025
Pulmonx (Nasdaq: LUNG) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day. Interested parties must register online to receive dial‑in details and a personal PIN. A live and archived webcast will be available in the Investors section at https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG) riferirà i risultati finanziari del terzo trimestre 2025 dopo la chiusura del mercato di mercoledì 29 ottobre 2025.
Il management terrà una conference call alle 13:30 PT / 16:30 ET nello stesso giorno. Le parti interessate devono registrarsi online per ricevere i dettagli di accesso e un PIN personale. Una webcast dal vivo e archiviata sarà disponibile nella sezione Investors all'indirizzo https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG) informará los resultados financieros del tercer trimestre de 2025 tras el cierre del mercado el miércoles 29 de octubre de 2025.
La dirección organizará una llamada de conferencia a las 1:30 p.m. PT / 4:30 p.m. ET ese mismo día. Las partes interesadas deben registrarse en línea para recibir los detalles de marcación y un PIN personal. Una transmisión en vivo y grabada estará disponible en la sección Inversores en https://investors.pulmonx.com/.
Pulmonx (나스닥: LUNG)는 2025년 3분기 재무 결과를 2025년 10월 29일 수요일 거래 마감 후에 발표합니다.
경영진은 같은 날 PT 1:30 / ET 4:30에 컨퍼런스 콜을 주최합니다. 이해 관계자는 다이얼 인 세부 정보와 개인 PIN을 받기 위해 온라인 등록해야 합니다. 라이브 및 아카이브 된 웹캐스트는 Investors 섹션의 https://investors.pulmonx.com/에서 이용할 수 있습니다.
Pulmonx (Nasdaq : LUNG) publiera les résultats financiers du troisième trimestre 2025 après la clôture du marché le mercredi 29 octobre 2025.
La direction animera une conférence téléphonique à 13 h 30 PT / 16 h 30 ET le même jour. Les parties intéressées doivent s'inscrire en ligne pour recevoir les détails d'accès et un code PIN personnel. Une webdiffusion en direct et archivée sera disponible dans la section Investisseurs sur https://investors.pulmonx.com/.
Pulmonx (Nasdaq: LUNG) wird die Finanzergebnisse des dritten Quartals 2025 nach Börsenschluss am Mittwoch, dem 29. Oktober 2025 melden.
Die Geschäftsführung wird am selben Tag um 13:30 PT / 16:30 ET eine Telefonkonferenz ausrichten. Interessierte Personen müssen sich online registrieren, um die Dial-in-Details und eine persönliche PIN zu erhalten. Eine Live- und Archiv-Webcast wird im Bereich Investoren unter https://investors.pulmonx.com/ verfügbar sein.
Pulmonx (ناسداك: LUNG) ستعلن عن نتائج الربع الثالث من عام 2025 بعد إغلاق السوق يوم الأربعاء 29 أكتوبر 2025.
ستستضيف الإدارة مكالمة مؤتمرات في 1:30 ظهراً بتوقيت المحيط الهادئ / 4:30 مساءً بتوقيت شرق الولايات المتحدة في نفس اليوم. يجب على الأطراف المعنية التسجيل عبر الإنترنت للحصول على تفاصيل الاتصال ورقم تعريف شخصي. سيكون هناك بث مباشر ومسجل متاح في قسم المستثمرون على https://investors.pulmonx.com/.
Pulmonx (纳斯达克：LUNG) 将在市场收盘后公布2025 年第三季度财务业绩，时间为2025 年 10 月 29 日星期三。
管理层将在同一天举行一场电话会议，时间为PT 1:30 / ET 4:30。感兴趣的方需在线注册以接收拨入详情和个人 PIN。现场直播和存档的网络广播将可在Investors部分的https://investors.pulmonx.com/查看。
- None.
- None.
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Wednesday, October 29, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will Pulmonx (LUNG) release Q3 2025 results?
What time is the Pulmonx Q3 2025 earnings call (LUNG)?
How can investors join the Pulmonx (LUNG) conference call?
Where can I watch the Pulmonx Q3 2025 webcast (LUNG)?
Will the Pulmonx (LUNG) webcast be archived after the call?
